Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Marcaine for obstetric pelvic pain (symphysiolysis)
MOH_2022-03-20_010687Phase 3Not yet recruiting
- Sponsor
- ד"ר גיל פומפ
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of bupivacaine in Pelvic girdle pain (PGP) and Symphysis pubis dysfunction (SPD) (2 arms), sponsored by ד"ר גיל פומפ. Primary endpoint: Pain intensity on visual analog scale. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
Pelvic girdle pain (PGP)Symphysis pubis dysfunction (SPD)
Beyond the preview
Go deeper on MOH_2022-03-20_010687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-20_010687.